Skip to main content
. 2014 Sep 15;111(39):14211–14216. doi: 10.1073/pnas.1409580111

Fig. 6.

Fig. 6.

Siglec-9 polymorphism reduces binding to tumor-associated ligands. (A) Flow cytometry, mean fluorescence intensity (MFI) of Siglec-9–Fc chimera or K131Q–Siglec–Fc chimera binding to LS180 and (B) A549 cell lines (n = 6). *P < 0.05, **P ;< 0.01. (C and D), Binding of Neu5Acα2–6-Lactose-polyacrylamide (C) or Neu5Acα2–3-N-actyl-lactosamine-polyacrylamide (D) to different Siglec-9–Fc chimeras. (E) Summary of findings. Inhibition of immunosurveillance by myelomonocytic cells (Left) or inhibition of M2 polarization (Right) via CD33r inhibitory Siglecs.